pyrroles has been researched along with Familial Nonmedullary Thyroid Cancer in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, J; Chen, Y; Liang, X; Ma, C; Sun, L; Sun, S; Tang, Q; Wang, S; Xu, M; Zhang, L; Zhao, D | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Alonso, T; Díez, JJ; Grande, E; Iglesias, P | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Ahn, SH; An, SY; Choi, IJ; Jeon, EH; Jeong, WJ; Mo, JH; Park, MW | 1 |
| Boni, G; Ferdeghini, M; Mariani, G; Monzani, F; Pasqualetti, G; Polini, A; Ricci, S; Tognini, S | 1 |
2 trial(s) available for pyrroles and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
5 other study(ies) available for pyrroles and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Charge Reversal Polypyrrole Nanocomplex-Mediated Gene Delivery and Photothermal Therapy for Effectively Treating Papillary Thyroid Cancer and Inhibiting Lymphatic Metastasis.
Topics: Cell Line, Tumor; Humans; Hyperthermia, Induced; Lymphatic Metastasis; Nanoparticles; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyroglobulin; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2015 |
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; Mice; Mutation; Nuclear Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; raf Kinases; Signal Transduction; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Off-Label Use; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2012 |